- Trial Phase
- Phase 2
- Time to Market
- Unknown — the Phase 2a study is closed to accrual, the company is seeking a partner to continue development. If partnered, earliest potential approval would likely be 3-5+ years away.
- Why 2/10
- Narazaciclib is a legacy asset; Traws Pharma has pivoted to antivirals and is actively seeking to out-license it. No dated binary catalyst (pivotal readout or PDUFA) is scheduled. The only potential catalyst would be a partnership announcement, which is unpredictable and undated. The drug's contribution to TRAW's equity story is minimal.
Narazaciclib is a non-core, legacy asset at Traws Pharma. The company's stock is driven entirely by its antiviral pipeline (tivoxavir marboxil for influenza, ratutrelvir for COVID-19), not by narazaciclib. Investors should not buy TRAW for this drug. Any partnership deal for narazaciclib would be a modest positive surprise but is unlikely to move the stock significantly given the company's ~$10M market cap and focus on antivirals.
Price Chart
Executive Summary
Narazaciclib is an oral multi-kinase inhibitor targeting CDK4/6, CSF1R, and ARK5 that Traws Pharma inherited from the Onconova/Trawsfynydd merger. It completed Phase 1/2 dose escalation in low-grade endometrioid endometrial cancer (LGEEC) in Q2 2024, establishing an RP2D. However, Traws has since pivoted entirely to antivirals (influenza, COVID-19) and explicitly labels narazaciclib a "legacy" asset that it is seeking to out-license. The drug faces fierce competition from three marketed CDK4/6 inhibitors (Pfizer's Ibrance, Novartis' Kisqali, Lilly's Verzenio) with billion-dollar sales. Traws is a micro-cap (~$10M market cap) with a going-concern warning, heavy dilution (up to $5.6M ATM offering, plus recent $60M PIPE with dilutive warrants), and analysts have downgraded the stock. For a TRAW investor, narazaciclib is a negligible value driver — the stock's fate rests on the antiviral pipeline.
How It Works
Narazaciclib is a multi-kinase inhibitor — it blocks several enzymes (CDK4, CDK6, CSF1R, ARK5) that cancer cells need to grow and divide. CDK4 and CDK6 are well-validated targets in cancer; three similar drugs (palbociclib, ribociclib, abemaciclib) are already FDA-approved and blockbuster sellers. Narazaciclib is designed to also hit additional targets (CSF1R, ARK5) to potentially overcome resistance to existing drugs and reduce side effects like low white blood cell counts (neutropenia).
Trial Status
Phase 1/2 dose escalation completed in Q2 2024. The recommended Phase 2 dose (RP2D) of 160mg daily in combination with letrozole 2.5mg was established for low-grade endometrioid endometrial cancer (LGEEC). The Phase 1/2 study (NCT05705505) is closed to accrual. No new company-sponsored trials have been initiated; Traws is actively seeking a partner to advance the program.
The Two-Sided Case
Upcoming Catalysts
- Potential partnership/out-licensing deal for narazaciclib — Traws is actively seeking one but timelines are unpredictable.
- Any presentation of existing Phase 1/2 data at a medical meeting could generate modest attention.
- If partnered, the partner may initiate new trials, but this is speculative and likely years out.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Traws Pharma, Inc. 424B5 TRAW ·Originating report